Brief: Acer Therapeutics Reports Q3 Loss Per Share $0.23
19/11/2021 22:30
Nov 19 (Reuters) - Acer Therapeutics Inc ACER.O :
* ACER THERAPEUTICS REPORTS Q3 2021 FINANCIAL RESULTS AND
PROVIDES
CORPORATE UPDATE
* Q3 LOSS PER SHARE $0.23
* BELIEVES CASH & CASH EQUIVALENTS ARE SUFFICIENT TO FUND
CURRENTLY ANTICIPATED OPERATING & CAPITAL REQUIREMENTS INTO
MID-2022
* CASH AND CASH EQUIVALENTS WILL BE SUFFICIENT INTO MID-2022
EXCLUDING SUPPORT FOR PLANNED ACER-801 AND EDSIVO CLINICAL
TRIALS
Source text for Eikon: ID:nGNX2HmmCc
Further company coverage: ACER.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Acer Therapeutics
See all newsBrief: Leading Independent Proxy Advisory Firms Iss And Glass Lewis Recommend Acer Therapeutics Shareholders Vote "For" The Proposed Merger And Related Proposals
U.S. STOCKS ON THE MOVE-UGI, SkyWest, Sage Therapeutics
Acer Therapeutics surges on Zevra buyout deal
Brief: Zevra Therapeutics To Acquire Acer Therapeutics, Expanding Its Rare Disease Portfolio And Adding Commercial Product
Swiss stocks - Factors to watch on August 31